2: Relative Receptor Binding Affinity and Clinical Pharmacodynamics

There is a move in clinical practice and literature (such as newer editions of Stahl’s text) away from "therapeutic classification" (e.g., "antipsychotic" or "antidepressant").
Terminology Preference: Modern practice favors "structural classification" or classifications based on pharmacodynamic and pharmacokinetic behavior.
Reasoning: Determining if a drug is an antipsychotic is less helpful than understanding its relative receptor binding affinity. These attributes determine both the beneficial clinical effects and the problematic side effects or adverse reactions, especially when used in combination with other medications.

The clinical response to a medical treatment is a complex outcome derived from numerous interacting variables. It is often described as more of an "art" than a simple calculation because of these moving parts.
The primary equation for clinical response involves three major categories:
- Pharmacodynamics: This describes what the drug does to the body. Key components include:
  - Affinity: The attraction of a drug for a specific receptor site.
  - Intrinsic Activity: The actual effect or change the drug produces once it has bound to the site of action.
- Pharmacokinetics: This describes what the body does to the drug. It determines the drug’s concentration at the site of action via four processes (ADME):
  - Absorption.
  - Distribution.
  - Metabolism.
  - Elimination.
- Patient Biological Characteristics: Unique factors that influence both PK and PD, including:
  - Genetic makeup.
  - Age.
  - Comorbid diseases.
  - Environmental factors.

Definition: Relative receptor binding affinity is the ratio of drug concentration required to bind to the site where the drug has its highest affinity compared to sites where it has a lower affinity.
Selectivity and Ratios:
- This concept explains how a drug's pharmacology changes as its dose increases.
- Large Ratio: A large ratio between the highest affinity site and lower affinity sites indicates the drug is more selective for a specific receptor.
- Small Ratio: A small ratio indicates the drug is less selective and will affect a wider multitude of receptor sites across a range of concentrations.
Dissociation Constant ( $K_i$ ): In scientific literature, binding affinity is represented by the value $K_i$ . This constant represents the concentration of a drug needed to bind to 50\text{%} of its target sites of action.

A drug will prioritize binding to the site for which it has the highest affinity (the site it is most avidly attracted to).
As the concentration or dose increases, the drug begins to "spill over" and bind to secondary sites with lower affinity.
Quantitative vs. Qualitative Effects: The effects at different sites may not just differ in magnitude (quantitative) but also in the nature of the effect (qualitative).
Clearance and the Dosing Rate: Concentration is mathematically determined by the dosing rate divided by the patient's ability to clear the drug ( $\text{Concentration} = \frac{\text{Dosing Rate}}{\text{Clearance}}$ ).
Clearance Factors:
- Cytochrome P450 (CYP450) System: Pathways that can be inhibited or induced by other drugs, significantly altering concentration without a change in dose.
- Organ Function: Liver problems (metabolism) or kidney problems (renal excretion) directly impact a patient’s ability to clear a drug.

Interpretation of Affinity Values: When looking at relative binding tables, a value of $1$ represents the highest affinity (the site divided by itself). The closer a value is to $1$ , the higher the affinity.
Quetiapine (Seroquel):
- Displays the highest affinity for the $\alpha_1$ and $H1$ receptors; these values are nearly identical.
- It will bind to these receptors first before affecting others.
Ziprasidone (Geodon):
- Displays a much higher affinity for the $5\text{-HT}_{2A}$ receptor compared to its other receptor targets.
Crucial Rule of Relative Affinity: Binding affinities are useful for examining the properties of a single drug. You cannot directly compare the binding values of one drug (e.g., Seroquel's $5\text{-HT}_{2A}$ ) to another (e.g., Ziprasidone's $5\text{-HT}_{2A}$ ) to determine comparative dosing.

Consider a hypothetical "mystery drug" that targets Receptor A (high affinity) and Receptor B (lower affinity).
If the drug has a much higher affinity for Receptor A, a clinician might need to increase the drug concentration tenfold ( $10 \times$ ) before it begins to affect Receptor B.
To achieve this, the dose must be increased significantly, or the patient’s clearance must be reduced sufficiently to reach that $10 \times$ concentration threshold.

Affinity Data for Quetiapine:
- $\alpha_1$ and $H1$ receptors have affinity values near $1$ .
- The Dopamine 2 (D2) receptor has a $K_i$ value of $23.9$ .
Concentration Thresholds: It takes approximately $15$ times (or more) the concentration of Quetiapine to begin binding to the D2 receptor than it does to bind to the $H1$ and $\alpha_1$ receptors.
Clinical Implications of Dosing:
- Low Doses ( $50\,mg$ to $100\,mg$ ): At these doses, Seroquel effectively only saturates $H1$ and $\alpha_1$ . It functions exclusively as a sedative-hypnotic for sleep.
- Antipsychotic Doses ( $400\,mg$ , $500\,mg$ , or $600\,mg$ ): To function as an antipsychotic, Seroquel requires a saturation level of 50\text{%} to 60\text{%} at the D2 receptor. This is only achievable at much higher concentrations.
Conclusion: Seroquel does not have meaningful antipsychotic properties at low doses; its psychiatric categorization is entirely dependent on its concentration-dependent receptor binding.

There is a move in clinical practice and literature (such as newer editions of Stahl’s text) away from "therapeutic classification" (e.g., "antipsychotic" or "antidepressant").
Terminology Preference: Modern practice favors "structural classification" or classifications based on pharmacodynamic and pharmacokinetic behavior.
Reasoning: Determining if a drug is an antipsychotic is less helpful than understanding its relative receptor binding affinity. These attributes determine both the beneficial clinical effects and the problematic side effects or adverse reactions, especially when used in combination with other medications.